Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2003 1
2006 1
2007 1
2008 2
2010 1
2011 1
2013 1
2014 1
2015 1
2016 6
2017 8
2018 11
2019 6
2020 4
2021 1
2022 3
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

42 results
Results by year
Filters applied: . Clear all
Page 1
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Fader AN, et al. Among authors: litkouhi b. Clin Cancer Res. 2020 Aug 1;26(15):3928-3935. doi: 10.1158/1078-0432.CCR-20-0953. Epub 2020 Jun 29. Clin Cancer Res. 2020. PMID: 32601075 Free PMC article. Clinical Trial.
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Fader AN, et al. Among authors: litkouhi b. J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584549 Clinical Trial.
Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience.
Devereaux KA, Weiel JJ, Pors J, Steiner DF, Ho C, Charu V, Suarez CJ, Renz M, Diver E, Karam A, Litkouhi B, Dorigo O, Kidd EA, Yang EJ, Folkins AK, Longacre TA, Howitt BE. Devereaux KA, et al. Among authors: litkouhi b. Mod Pathol. 2022 May;35(5):688-696. doi: 10.1038/s41379-021-00963-y. Epub 2021 Nov 6. Mod Pathol. 2022. PMID: 34743187
Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma.
Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Deshmukh U, et al. Among authors: litkouhi b. Reprod Sci. 2019 May;26(5):600-608. doi: 10.1177/1933719118778801. Epub 2018 May 29. Reprod Sci. 2019. PMID: 29843577
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. Bonazzoli E, et al. Among authors: litkouhi b. Gynecol Oncol. 2019 Apr;153(1):158-164. doi: 10.1016/j.ygyno.2019.01.002. Epub 2019 Jan 7. Gynecol Oncol. 2019. PMID: 30630630 Free PMC article.
Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer.
Lester-Coll NH, Young MR, Park HS, Ratner ES, Litkouhi B, Damast S. Lester-Coll NH, et al. Among authors: litkouhi b. Int J Gynecol Cancer. 2017 Nov;27(9):1904-1911. doi: 10.1097/IGC.0000000000001095. Int J Gynecol Cancer. 2017. PMID: 28763364
42 results